Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution.

Abstract:

PURPOSE:Breast terminal duct lobular units undergo two distinctive physiological processes of involution: age-related lobular involution (LI), which is gradual and associated with decreased breast cancer risk, and postlactational involution, which is relatively precipitous, occurs with weaning, and has been associated with potentiation of tumor aggressiveness in animal models. Here we assessed whether markers of postlactational involution are associated with ongoing LI in a retrospective tissue cohort. METHODS:We selected 57 women from the Mayo Clinic Benign Breast Disease Cohort who underwent multiple biopsies and who were average age 48 at initial biopsy. Women were classified as having progressive or non-progressive LI between initial and subsequent biopsy. Serial tissue sections were immunostained for plasminogen, matrix metalloproteinase 9 (MMP-9), phospho-STAT3 (pSTAT3), tenascin C, Ki67, CD44, cytokeratin 14 (CK14), cytokeratin 19 (CK19), and c-myc. All but Ki67 were digitally quantified. Associations between maximal marker expression per sample and progressive versus non-progressive LI were assessed using logistic regression and adjusted for potential confounders. RESULTS:While no biomarker showed statistically significant association with LI progression when evaluated individually, lower expression of pSTAT3 (OR 0.35, 95% CI 0.13-0.82, p = 0.01) and higher expression of plasminogen (OR 2.89, 95% CI 1.14-8.81, p = 0.02) were associated with progressive LI in models simultaneously adjusted for all biomarkers. Sensitivity analyses indicated that the strengthening in association for pSTAT3 and plasminogen with progressive LI was due to collinearity between these two markers. CONCLUSIONS:This is the first study to identify biomarkers of active LI. Our findings that plasminogen and pSTAT3 are significantly associated with LI suggest that they may represent signaling nodes or biomarkers of pathways common to the processes of postlactational involution and LI.

authors

Stallings-Mann ML,Heinzen EP,Vierkant RA,Winham SJ,Hoskin TL,Denison LA,Nassar A,Hartmann LC,Visscher DW,Frost MH,Sherman ME,Degnim AC,Radisky DC

doi

10.1007/s10549-017-4413-3

subject

Has Abstract

pub_date

2017-11-01 00:00:00

pages

133-143

issue

1

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-017-4413-3

journal_volume

166

pub_type

杂志文章
  • Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.

    abstract::The gene for Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (Pnck), a novel calmodulin kinase, is expressed in roughly one-third of human breast tumors, but not in adjoining normal tissues. Pnck alters EGFR stability and function, prompting this study to determine if Pnck expression has implications for HER-2...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3337-z

    authors: Deb TB,Zuo AH,Barndt RJ,Sengupta S,Jankovic R,Johnson MD

    更新日期:2015-04-01 00:00:00

  • Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer.

    abstract::Fresh organically grown pomegranates (Punica granatum L.) of the Wonderful cultivar were processed into three components: fermented juice, aqueous pericarp extract and cold-pressed or supercritical CO2-extracted seed oil. Exposure to additional solvents yielded polyphenol-rich fractions ('polyphenols') from each of th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1014405730585

    authors: Kim ND,Mehta R,Yu W,Neeman I,Livney T,Amichay A,Poirier D,Nicholls P,Kirby A,Jiang W,Mansel R,Ramachandran C,Rabi T,Kaplan B,Lansky E

    更新日期:2002-02-01 00:00:00

  • Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.

    abstract:RATIONALE:Survival after loco-regional failure (LRF) of breast cancer was investigated at the population level. METHODS:Using the Stockholm cancer registry, 2698 patients diagnosed with LRF between 1980 and 2014 were identified and divided into three cohorts by year of LRF diagnosis. Post-relapse event-free survival (...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4936-2

    authors: Falato C,Taylor SK,Szulkin R,Nordblom A,Eriksson L,Sofiadis A,Fredriksson I,Hartman J,Bergh J,Foukakis T

    更新日期:2018-12-01 00:00:00

  • Droloxifene, a new antiestrogen: its role in metastatic breast cancer.

    abstract::Droloxifene, a new antiestrogen, has theoretical advantages over tamoxifen based on preclinical data. These include higher affinity to the estrogen receptor, higher antiestrogenic to estrogenic ratio, and more effective inhibition of cell growth and division in ER positive cell lines, as well as less toxicity, includi...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/BF00689679

    authors: Rauschning W,Pritchard KI

    更新日期:1994-01-01 00:00:00

  • 99m-Tc-tetrofosmin scintigraphy for the evaluation of suspicious palpable and non-palpable breast lesions.

    abstract:PURPOSE:To assess the value of 99m-Tc-tetrofosmin (tetrofosmin) scintigraphy in patients with palpable and nonpalpable breast lesions. PATIENTS AND METHODS:Prospective, blinded trial. One hundred and fifty-nine consecutive patients with 163 breast lesions detected by clinical examination and mammography were included....

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006442622417

    authors: Obwegeser R,Berghammer P,Muellauer-Ertl S,Kubista E,Sinzinger H

    更新日期:2000-08-01 00:00:00

  • Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.

    abstract::Goserelin ('Zoladex'), a luteinizing hormone-releasing hormone (LHRH) agonist induces reversible ovarian ablation in premenopausal women. It is the most extensively studied LHRH agonist for the treatment of breast cancer and data from a large clinical trial program show that, alone or in combination with tamoxifen, go...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1020309715942

    authors: Jonat W

    更新日期:2002-10-01 00:00:00

  • Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis.

    abstract:BACKGROUND:The aims of this study were to define the distribution of caveolin 2 (CAV2) in frozen and formalin fixed, paraffin embedded (FFPE) normal breast samples and the significance of CAV2 expression in breast cancer. METHODS:Caveolin 2 distribution in frozen and paraffin-embedded whole tissue sections of normal b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9718-1

    authors: Savage K,Leung S,Todd SK,Brown LA,Jones RL,Robertson D,James M,Parry S,Rodrigues Pinilla SM,Huntsman D,Reis-Filho JS

    更新日期:2008-07-01 00:00:00

  • Estradiol and progesterone receptors in breast cancer: prognostic value after relapse.

    abstract::The prognostic significance of estradiol (ER) and progesterone receptors (PgR) for survival from relapse has been studied in two groups of breast cancer patients: group 1, 35 patients in whom receptor levels were measured at the time of mastectomy; group II, 49 patients in whom receptor levels were measured at the tim...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805988

    authors: Bonneterre J,Horner D,Peyrat JP,Vandewalle B,Cambier L,Demaille A

    更新日期:1985-01-01 00:00:00

  • Inflammatory breast cancer (IBC): clues for targeted therapies.

    abstract::Inflammatory breast cancer (IBC) is the most aggressive type of advanced breast cancer characterized by rapid proliferation, early metastatic development and poor prognosis. Since there are few preclinical models of IBC, there is a general lack of understanding of the complexity of the disease. Recently, we have devel...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2600-4

    authors: Fernandez SV,Robertson FM,Pei J,Aburto-Chumpitaz L,Mu Z,Chu K,Alpaugh RK,Huang Y,Cao Y,Ye Z,Cai KQ,Boley KM,Klein-Szanto AJ,Devarajan K,Addya S,Cristofanilli M

    更新日期:2013-07-01 00:00:00

  • BRCA testing and outcomes in women with breast cancer.

    abstract:MAIN PURPOSE:Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carriers (BRCAwt) with breast cancer. RESEARCH QUESTION:The re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06038-x

    authors: Stenehjem DD,Telford C,Unni SK,Bauer H,Sainski A,Deka R,Schauerhamer MB,Ye X,Tak CR,Ma J,Dalvi TB,Gutierrez L,Kaye JA,Tyczynski JE,Brixner DI,Biskupiak JE

    更新日期:2021-01-03 00:00:00

  • Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.

    abstract:BACKGROUND:Gemcitabine (G) and vinorelbine (V) have favorable safety profile and antitumor activity in metastatic breast cancer. To exploit their different mechanism of action and lack of overlapping toxicity, we performed a phase I and II study of G and V in combination. PATIENTS AND METHODS:Fifty-three patients with...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1013034311284

    authors: Mariani G,Tagliabue P,Zucchinelli P,Brambilla C,Demicheli R,Villa E,Marchianò A,Valagussa P,Bonadonna G,Gianni L

    更新日期:2001-12-01 00:00:00

  • Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

    abstract::Molecular profiles of asynchronous breast cancer metastases are of clinical relevance to individual patients' treatment, whereas the role of profiles in synchronous lymph node metastases is not defined. The present study aimed to assess individual biomarkers and molecular subtypes according to the St Gallen classifica...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2617-8

    authors: Falck AK,Bendahl PO,Chebil G,Olsson H,Fernö M,Rydén L

    更新日期:2013-07-01 00:00:00

  • Insulin-like growth factor expression in breast cancer epithelium and stroma.

    abstract::The insulin-like growth factors (IGFs) are mitogens for many cancer cell types. In breast cancer cells, IGF-I and IGF-II have both been shown to stimulate cell proliferation. However, IGF-I mRNA has not been found in human breast cancer cell lines, making it unlikely that IGF-I is commonly expressed as an autocrine gr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF01833330

    authors: Cullen KJ,Allison A,Martire I,Ellis M,Singer C

    更新日期:1992-01-01 00:00:00

  • Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review.

    abstract::The association of smoking with outcomes following breast cancer prognosis is not well understood. In a cohort study called Life After Cancer Epidemiology (LACE), 2,265 women diagnosed with breast cancer were followed for a median of 12 years. We used multivariable proportional-hazards models to determine whether smok...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-012-2276-1

    authors: Braithwaite D,Izano M,Moore DH,Kwan ML,Tammemagi MC,Hiatt RA,Kerlikowske K,Kroenke CH,Sweeney C,Habel L,Castillo A,Weltzien E,Caan B

    更新日期:2012-11-01 00:00:00

  • Early self-reported impairments in arm functioning of primary breast cancer patients predict late side effects of axillary lymph node dissection: results from a population-based cohort study.

    abstract:OBJECTIVES:Improvements in the life expectancy of women with breast cancer raise important questions how to improve quality of life (QoL) for women sustaining complications and side effects of cancer treatment. The presented study examined the prevalence of arm morbidity in a cohort of primary breast cancer patients ov...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9247-3

    authors: Albert US,Koller M,Kopp I,Lorenz W,Schulz KD,Wagner U

    更新日期:2006-12-01 00:00:00

  • Galectin-3 and L1 retrotransposons in human breast carcinomas.

    abstract::Galectin-3 is a galactoside binding protein found at elevated levels in a wide variety of neoplastic cells and thought to be involved in cognitive cellular interactions during transformation and metastasis. Previously, we have shown that introduction of human galectin-3 (Mr 31,000) cDNA into the human breast cancer ce...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005913810250

    authors: Nangia-Makker P,Sarvis R,Visscher DW,Bailey-Penrod J,Raz A,Sarkar FH

    更新日期:1998-05-01 00:00:00

  • Health disparities in breast cancer: biology meets socioeconomic status.

    abstract::Breast cancer is the most common cancer in women worldwide, accounting for just over 1 million new cases annually. Population-based statistics show that globally, when compared to whites, women of African ancestry (AA) tend to have more aggressive breast cancers that present more frequently as estrogen receptor negati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-010-0827-x

    authors: Dunn BK,Agurs-Collins T,Browne D,Lubet R,Johnson KA

    更新日期:2010-06-01 00:00:00

  • Trends of breast cancer incidence and risk factor prevalence over 25 years.

    abstract:INTRODUCTION:To examine the trends in the prevalence of breast cancer risk factors in relation to breast cancer incidence trends and to explore whether the changes in risk factors differed by ethnicity in Hawaii over a 25-year period. METHODS:We pooled 17 population-based epidemiological studies conducted in Hawaii be...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9129-0

    authors: Maskarinec G,Zhang Y,Takata Y,Pagano I,Shumay DM,Goodman MT,Le Marchand L,Nomura AM,Wilkens LR,Kolonel LN

    更新日期:2006-07-01 00:00:00

  • A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

    abstract:PURPOSE:The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-018-4770-6

    authors: O'Shaughnessy J,DeMichele A,Ma CX,Richards P,Yardley DA,Wright GS,Kalinsky K,Steis R,Diab S,Kennealey G,Geschwindt R,Jiang W,Rugo HS

    更新日期:2018-08-01 00:00:00

  • XPD common variants and their association with melanoma and breast cancer risk.

    abstract::There are suggestions in the literature that common variants in the XPD gene may be associated with an altered risk of melanoma and breast cancer. To establish if the XPD common variants Asp312Asn and Lys751Gln are associated with an increased melanoma or breast cancer risk we performed an association study based on g...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9151-2

    authors: Debniak T,Scott RJ,Huzarski T,Byrski T,Masojć B,van de Wetering T,Serrano-Fernandez P,Górski B,Cybulski C,Gronwald J,Debniak B,Maleszka R,Kładny J,Bieniek A,Nagay L,Haus O,Grzybowska E,Wandzel P,Niepsuj S,Narod SA,

    更新日期:2006-07-01 00:00:00

  • Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer.

    abstract::SLX4 coordinates three structure-specific endonucleases in the DNA damage response. One subtype of Fanconi anaemia, FA-P, has recently been attributed to biallelic SLX4 gene mutations. To investigate whether monoallelic SLX4 gene defects play some role in the inherited component of breast cancer susceptibility, in thi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1681-1

    authors: Landwehr R,Bogdanova NV,Antonenkova N,Meyer A,Bremer M,Park-Simon TW,Hillemanns P,Karstens JH,Schindler D,Dörk T

    更新日期:2011-12-01 00:00:00

  • A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk.

    abstract::In this paper, we report findings from a family-based association study examining the association between polymorphisms in two key estrogen-metabolism genes CYP1B1 (codon 432 G --> C and codon 453 A --> G variants) and COMT (codon 158 G --> A variant) and female breast cancer. We conducted the study among 280 nuclear ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000025401.60794.68

    authors: Ahsan H,Chen Y,Whittemore AS,Kibriya MG,Gurvich I,Senie RT,Santella RM

    更新日期:2004-05-01 00:00:00

  • Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer.

    abstract::Neurofibromatosis type 1 (NF1) is a common dominant autosomal disorder caused by mutations in the NF1 gene. The main manifestations of NF1 are café-au-lait spots, neurofibromas, intertriginous freckling, Lisch nodules, and malignancy, including peripheral nerve sheath tumors, central nervous system gliomas, and a vari...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2538-6

    authors: Campos B,Balmaña J,Gardenyes J,Valenzuela I,Abad O,Fàbregas P,Volpini V,Díez O

    更新日期:2013-06-01 00:00:00

  • Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.

    abstract::Paclitaxel and vinorelbine are among the most active new agents in metastatic breast cancer. Both in vitro and in vivo studies have shown that the combined administration of these two microtubule-targeting agents is feasible and worthwhile. Based on the promising preclinical data, patients with metastatic breast cance...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1005848921895

    authors: Tortoriello A,Facchini G,Caponigro F,Santangelo M,Benassai G,Persico G,Citarella A,Carola M,Marzano N,Iaffaioli RV

    更新日期:1998-01-01 00:00:00

  • Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the Cancer Prevention Study-II Nutrition Cohort.

    abstract:PURPOSE:Nearly half of the 3.5 million female breast cancer survivors in the US are aged 65 years or older at diagnosis, yet little is known about associations of obesity and physical activity with breast cancer-specific mortality (BCSM) among older survivors. METHODS:Between 1992 and 2013, 5254 women in the Cancer Pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4470-7

    authors: Maliniak ML,Patel AV,McCullough ML,Campbell PT,Leach CR,Gapstur SM,Gaudet MM

    更新日期:2018-01-01 00:00:00

  • Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer.

    abstract::The androgen receptor (AR) is a transcription factor mediating the action of androgens. The AR gene is localized on chromosome X and it contains a series of CAG trinucleotide repeats. The length of the CAG repeats varies among individuals and this polymorphism is believed to be related to AR transcriptional activity. ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006356502820

    authors: Yu H,Bharaj B,Vassilikos EJ,Giai M,Diamandis EP

    更新日期:2000-01-01 00:00:00

  • Transcriptional profiles of progestogen effects in the postmenopausal breast.

    abstract::Estrogen plus progestin hormone therapy has been associated with increased breast proliferation, breast density, and breast cancer risk in postmenopausal women, beyond that seen with estrogen alone. The goal of this study was to evaluate progestogen effects on gene expression profiles in the breast contributing to thi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0003-8

    authors: Wood CE,Register TC,Cline JM

    更新日期:2009-03-01 00:00:00

  • Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.

    abstract::The association between promoter methylation status and survival was investigated in a large cohort of women with breast cancer, participants in the Long Island Breast Cancer Study Project. Archived tumor tissues (n = 839) were collected from women diagnosed with a first primary invasive or in situ breast cancer in 19...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1712-y

    authors: Cho YH,Shen J,Gammon MD,Zhang YJ,Wang Q,Gonzalez K,Xu X,Bradshaw PT,Teitelbaum SL,Garbowski G,Hibshoosh H,Neugut AI,Chen J,Santella RM

    更新日期:2012-01-01 00:00:00

  • Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells.

    abstract::The present study was undertaken to compare ROH growth responsiveness between normal human mammary epithelial cells (HMECs), estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cells, and assess whether this responsiveness is correlated with differences in ROH metabolism, particularly RA synthes...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1014815112078

    authors: Hayden LJ,Satre MA

    更新日期:2002-03-01 00:00:00

  • Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

    abstract:PURPOSE:Androgen receptor (AR) and AR signaling pathways are thought to play a role in breast cancer (BC) and are potentially related to treatment responses and outcomes. Ankyrin 3 (ANK3) is associated with AR stability in cancer cells. In the present study, we investigated the clinicopathological utility of ANK3 expre...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05216-w

    authors: Kurozumi S,Joseph C,Raafat S,Sonbul S,Kariri Y,Alsaeed S,Pigera M,Alsaleem M,Nolan CC,Johnston SJ,Aleskandarany MA,Ogden A,Fujii T,Shirabe K,Martin SG,Alshankyty I,Mongan NP,Ellis IO,Green AR,Rakha EA

    更新日期:2019-07-01 00:00:00